Blog - Page 832 of 5751 - QualityStocks

WednesdayFeb 08, 2023 11:37 am

QualityStocksNewsBreaks – Creatd Inc. (CRTD) Approved to Dual List on Upstream

Creatd (OTCQB: CRTD), a company with a mission to provide economic opportunities to creators and brands, on Tuesday announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited. According to the update, the company will commence trading on Upstream under the ticker symbol CRTD at 10:00 a.m. ET on Feb. 14, 2023. “As chairman and CEO, my focus remains on creating long-term value for verified CRTD shareholders and on fostering a higher quality market environment for our stock,” said CRTD’s Jeremy Frommer in…

WednesdayFeb 08, 2023 11:26 am

QualityStocksNewsBreaks – Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) Receives $24M Investment from Leading Global Mining Company

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF) has entered into a subscription agreement with Anglo American resulting in an estimated $24 million investment in Canada Nickel; the investment is at a price of $1.95 per common share, representing a 10% premium to the 30-day volume weighted average price ("VWAP") and making Anglo American a 9.9% shareholder when the transaction is completed. According to the announcement, this is a key milestone in the company’s efforts to advance its Crawford Nickel Project toward production. The agreement also calls for Canada Nickel to enter into a binding Offtake Term Sheet with Anglo American at closing, giving Anglo American exclusive…

WednesdayFeb 08, 2023 11:15 am

QualityStocksNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate in a question-and-answer session. Interested parties should visit https://ibn.fm/iVpOP to register for the webinar. To view the full press release, visit https://ibn.fm/l9PMs About India Globalization Capital Inc. IGC develops advanced cannabinoid-based formulations for treating diseases…

WednesdayFeb 08, 2023 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Commissions Demonstration Plant; Plans for Louisiana Strategic Metals Complex

Ucore’s RapidSX(TM) Demonstration Plant will be located within the company’s 5000 square foot Commercialization and Demonstration Facility in Kingston, Ontario A Strategic Metals Complex is being planned in Louisiana with an initial capacity of 2,000 tonnes per annum and increasing to production of 5,000 tonnes Cerium, neodymium, lanthanum, praseodymium, yttrium, and dysprosium are expected to remain the most sought-after REEs, with high demands in magnet manufacturing and the automobile industry The global rare earth element market was valued at $2.8 billion in 2018 and is expected to grow at a CAGR of 10.4% through 2025 Ucore Rare Metals (TSX.V: UCU)…

WednesdayFeb 08, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth

Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating the SARS-COV-2 virus in a hamster population With COVID as first target, the company’s pipeline aims to provide effective medical responses to other disorders such asthma, psoriasis, psoriatic arthritis, and macular degeneration Immunotherapeutic product innovator…

WednesdayFeb 08, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – Technology Behind Patented Disruptive DehydraTECH(TM) Drug Delivery Platform

Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending Speaking during a late…

TuesdayFeb 07, 2023 1:52 pm

QualityStocksNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar and chronic pain,” a recent article reads. “In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a…

TuesdayFeb 07, 2023 1:35 pm

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Epitomizing Potential Success with Focus on Less Traditional Mining Jurisdictions

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, boasts one of the most potentially significant silver and tin deposits within the Cerro Rico region and has recently looked to expand its addressable deposit through the acquisition of the adjoining Mina Casiterita and Mina Hoyada properties. “Marc Bristow, the CEO of Barrick Gold Corp, told investors during his keynote speech at the Mines & Money London conference that the future of mining no longer lay in the traditional, over-explored jurisdictions of prior…

TuesdayFeb 07, 2023 12:18 pm

QualityStocksNewsBreaks – Utopia VR President Featured in Latest Episode of Bell2Bell Podcast

Utopia VR, one of the world’s first metaverse-as-a-service solutions for business, is featured in the most recent release from The Bell2Bell Podcast. During the interview, Utopia VR president Stuart Gray and Bell2Bell host Jonathan Keim discuss how the VR space has evolved and Utopia VR’s entry into the space. In addition, Gray provided a tour of one of Utopia VR’s 3D environments designed to help professionals collaborate and socialize. Gray also outlined the company’s business-focused strategy, explained how Utopia VR is integrating artificial intelligence (“AI”) into its platform and shared his vision for the future of the metaverse. The Bell2Bell…

TuesdayFeb 07, 2023 11:56 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first patient in Spain. As part of the trial, the company has opened 37 of 59 planned clinical trial sites; the sites are located in the United States, Italy, France, Spain and Switzerland. The company noted that it plans an interim analysis of the study when…

Site Search

Company Search